Replies to post #85586 on Biotech Values

[DewDiligence]

GSK’s CEO, Andrew Witty, says the HIV joint venture with PFE (#msg-37066684) has obtained final regulatory clearance and will be formally launched with an announcement today or tomorrow (Nov 2 or Nov 3).

Source: GSK 3Q09 CC (10/28/09)

[genisi]

IDIX has initiated a Phase II clinical trial evaluating IDX184+ SoC for 14 days and doses of up to 200mg (Patients will continue on treatment with pegylated interferon and ribavirin for 14 more days):

http://finance.yahoo.com/news/Idenix-Pharmaceuticals-prnews-2318795928.html/print?x=0

[DewDiligence]

IDIX 2009-2010 News Flow

[Updated for start of phase-2 IDX184 trial (#msg-43179141).]


HCV


4Q09: Start phase-1 trial of IDX375. (A CTA was submitted during 3Q09.)

4Q09: Submit IND/CTA for IDX316. Start phase-1 trial in 1Q010.

Late 2009 or more likely (IMO) 1H10: Ink IDX184 partnership.

Mid 2010: Report top-line phase-2 data for IDX184.

Nov 2010: Present complete phase-2 data for IDX184 at AASLD.

2010(?): Submit IND/CTA for lead compound from NS5A program.


HIV

Early 2010: GSK* starts phase-2 IDX899 trial.

*GSK is the operator of ViiV Healthcare, the HIV joint venture with PFE (#msg-43254006).